Carboxyamidotriazole, formerly known as CAI; RFE-007; NSC-609974; and L-651582, is a novel inhibitor of both cAMP-phosphodiesterases and GMP-phosphodiesterases. Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition. Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-κB activation, and colonic fibrosis. References: Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J, Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68. doi: 10.3892/or.2016.4945. Epub 2016 Jul 18. PubMed PMID: 27430982; PubMed Central PMCID: PMC4968618.

纯度：≥98%

CAS：99519-84-3